MX2018003983A - Metodo de tratamiento de trastornos asociados a la via del receptor de melanocortina-4. - Google Patents

Metodo de tratamiento de trastornos asociados a la via del receptor de melanocortina-4.

Info

Publication number
MX2018003983A
MX2018003983A MX2018003983A MX2018003983A MX2018003983A MX 2018003983 A MX2018003983 A MX 2018003983A MX 2018003983 A MX2018003983 A MX 2018003983A MX 2018003983 A MX2018003983 A MX 2018003983A MX 2018003983 A MX2018003983 A MX 2018003983A
Authority
MX
Mexico
Prior art keywords
treating
associated disorders
receptor pathway
melanocortin
subject
Prior art date
Application number
MX2018003983A
Other languages
English (en)
Inventor
H T Van Der Ploeg Leonardus
Henderson Bart
Kuhnen Peter
Original Assignee
Rhythm Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhythm Pharmaceuticals Inc filed Critical Rhythm Pharmaceuticals Inc
Publication of MX2018003983A publication Critical patent/MX2018003983A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • C07K14/685—Alpha-melanotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cell Biology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La descripción está relacionada con un método para tratar un trastorno, tal como el síndrome de Prader Willi (PWS), obesidad o hiperfagia, en un sujeto que usa un agonista del receptor de melanocortina-4 (MC4R). También se describe un método para tratar a un sujeto que tiene una deficiencia en la vía pro-opiomelanocortina (POMC)-MC4R, tal como un sujeto POMC-nulo o PCSK-nulo, usando un agonista MC4R.
MX2018003983A 2015-09-30 2016-09-29 Metodo de tratamiento de trastornos asociados a la via del receptor de melanocortina-4. MX2018003983A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562235003P 2015-09-30 2015-09-30
PCT/US2016/054457 WO2017059076A1 (en) 2015-09-30 2016-09-29 Method of treating melanocortin-4 receptor pathway-associated disorders

Publications (1)

Publication Number Publication Date
MX2018003983A true MX2018003983A (es) 2018-11-09

Family

ID=57138146

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018003983A MX2018003983A (es) 2015-09-30 2016-09-29 Metodo de tratamiento de trastornos asociados a la via del receptor de melanocortina-4.
MX2023003358A MX2023003358A (es) 2015-09-30 2018-03-28 Agonista del receptor de melanocortina-4 (mc4r) para el tratamiento de trastornos asociados a la via del mc4r.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023003358A MX2023003358A (es) 2015-09-30 2018-03-28 Agonista del receptor de melanocortina-4 (mc4r) para el tratamiento de trastornos asociados a la via del mc4r.

Country Status (17)

Country Link
US (4) US20180215790A1 (es)
EP (4) EP3356386B1 (es)
JP (6) JP6940853B2 (es)
KR (1) KR20180063221A (es)
CN (2) CN108431023B (es)
AU (5) AU2016330773A1 (es)
BR (1) BR112018006674A2 (es)
CA (2) CA3000670A1 (es)
DK (1) DK3356386T3 (es)
FI (1) FI3356386T3 (es)
HK (1) HK1259424A1 (es)
IL (3) IL299541A (es)
MA (2) MA43040A (es)
MX (2) MX2018003983A (es)
PT (1) PT3356386T (es)
SG (1) SG10202101510XA (es)
WO (2) WO2017059075A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3539551T (pt) 2011-12-29 2021-11-04 Rhythm Pharmaceuticals Inc Método de tratamento de distúrbios associados ao recetor de melanocortina-4 em portadores heterozigóticos
EP3356386B1 (en) * 2015-09-30 2024-02-14 Rhythm Pharmaceuticals, Inc. Method of treating melanocortin-4 receptor pathway-associated disorders
RU2020119425A (ru) * 2017-11-15 2021-12-15 Ритм Фармасьютикалз, Инк. Составы на основе пептидов с длительным высвобождением
WO2019162312A1 (en) 2018-02-20 2019-08-29 Charité - Universitätsmedizin Berlin Mc4r agonist efficacy in subjects with mc4r deficiencies and impaired nfat signaling
US20210221867A1 (en) 2018-05-15 2021-07-22 Novo Nordisk A/S Compounds Capable of Binding to Melanocortin 4 Receptor
CN108841932B (zh) * 2018-07-13 2021-03-12 东北农业大学 一种预示和鉴定鸡腹部脂肪量的分子标记方法及应用
EP4146827A1 (en) * 2020-05-04 2023-03-15 Regeneron Pharmaceuticals, Inc. Proprotein convertase subtilisin/kexin type 1 (pcsk1) variants and uses thereof
CN116507353A (zh) * 2020-09-24 2023-07-28 节奏制药公司 治疗黑皮质素-4受体通路相关病症的方法
WO2024083843A1 (en) 2022-10-18 2024-04-25 Confo Therapeutics N.V. Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5226895A (en) 1989-06-05 1993-07-13 Eli Lilly And Company Multiple dose injection pen
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
AU1860697A (en) 1995-09-08 1997-07-28 Visionary Medical Products Corporation Pen-type injector drive mechanism
US5688251A (en) 1995-09-19 1997-11-18 Becton Dickinson And Company Cartridge loading and priming mechanism for a pen injector
US7319107B2 (en) 2001-11-08 2008-01-15 Johnson & Johnson Consumer Companies, Inc. 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators
DE10251673A1 (de) 2001-11-09 2003-07-10 Hoffmann La Roche Alström-Syndrom-Gen, Genvarianten, codiertes Protein und Verfahren zur Diagnose des Alström-Syndroms
EP1594986B1 (de) 2003-02-19 2011-07-13 Universität Duisburg-Essen Verwendung einer genveränderung im humanen gnas-gen zur vorhersage von erkrankungsrisiken, krankheitsverläufen und zur vorhersage des ansprechens auf krankheitstherapien
GB0304822D0 (en) 2003-03-03 2003-04-09 Dca Internat Ltd Improvements in and relating to a pen-type injector
DE602004012403T2 (de) 2003-04-29 2009-03-19 Orexigen Therapeutics, Inc., La Jolla Zusammensetzungen zur beeinflussung des gewichtsverlusts
US7968548B2 (en) 2003-05-01 2011-06-28 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine compounds with diamine groups
AU2004251616A1 (en) 2003-06-19 2005-01-06 Eli Lilly And Company Melanocortin receptor 4(MC4) agonists and their uses
US7910101B2 (en) * 2004-10-25 2011-03-22 Centocor, Inc. Melanocortin receptor binding mimetibodies, compositions, methods and uses
CA3228910A1 (en) * 2005-07-08 2007-01-18 Ipsen Pharma S.A.S Melanocortin receptor ligands
CA2614678A1 (en) 2005-07-08 2007-01-18 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R Ligands of melanocortin receptors
US8247530B2 (en) 2005-11-08 2012-08-21 Palatin Technologies, Inc. N-alkylated cyclic peptide melanocortin agonists
US8114844B2 (en) 2006-03-30 2012-02-14 Palatin Technologies, Inc. Linear and cyclic melanocortin receptor-specific peptidomimetics
JP2010516653A (ja) 2007-01-18 2010-05-20 ノボ・ノルデイスク・エー／エス 肥満の治療に使用される新規ペプチド
US20100016238A1 (en) 2007-01-18 2010-01-21 Novo Nordisk A/S Peptides for Use in the Treatment of Obesity
JP2010516652A (ja) 2007-01-18 2010-05-20 ノボ・ノルデイスク・エー／エス 肥満の治療に使用される新規ペプチド
WO2008087189A2 (en) 2007-01-18 2008-07-24 Novo Nordisk A/S Peptides for use in the treatment of obesity
EP1974729A1 (en) 2007-03-28 2008-10-01 Santhera Pharmaceuticals (Schweiz) AG Substituted imidazopyridine derivates as melanocortin- 4 receptor antagonists
CA2689016C (en) 2007-05-25 2014-08-12 Ipsen Pharma S.A.S. Melanocortin receptor ligands modified with hydantoin
EP2019100A1 (en) 2007-07-19 2009-01-28 Santhera Pharmaceuticals (Schweiz) AG Substituted heteroarylpiperidine derivatives as melanocortin-4 receptor modulators
BRPI0909947A2 (pt) 2008-06-09 2017-06-27 Palatin Technologies Inc '' peptídeo cíclico, composição farmacêutica, método de tratamento de uma doença, indicação, condição ou síndrome mediada por receptor de melanocortina em seres humanos ou mamíferos não humanos, e, método de tratamento de condição que reage a alterações da função de receptor de melanocortina em seres humanos ou mamíferos não humanos''
US20090305960A1 (en) 2008-06-09 2009-12-10 Palatin Technologies, Inc Melanocortin Receptor-Specific Peptides for Treatment of Obesity / 669
MX2011001405A (es) 2008-08-06 2011-03-21 Pfizer Ltd Compuestos de diazepina y diazocano como agonistas de mc4.
WO2010025142A1 (en) 2008-08-29 2010-03-04 Transtech Pharma, Inc. Substituted aminothiazole derivatives, pharmaceutical compositions, and methods of use
US9393369B2 (en) 2008-09-15 2016-07-19 Medimop Medical Projects Ltd. Stabilized pen injector
EP2168965A1 (en) 2008-09-25 2010-03-31 Santhera Pharmaceuticals (Schweiz) AG Substituted imidazopyridine, imidazopyrazine, imidazopyridazine and imidazopyrimidine derivatives as melanocortin-4 receptor antagonists
WO2010037081A1 (en) 2008-09-29 2010-04-01 Palatin Technologies, Inc. Melanocortin receptor-specific spiro-piperidine compounds
FR2937868B1 (fr) 2008-11-04 2010-11-05 Galderma Res & Dev Composes antagonistes des recepteurs de la melanocortine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
FR2937973B1 (fr) 2008-11-04 2010-11-05 Galderma Res & Dev Modulateurs des recepteurs de la melanocortine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
UA99555C2 (en) 2008-11-12 2012-08-27 Элджи Лайф Саенсез Лтд. Melanocortin receptor agonists
US20120021973A1 (en) 2008-11-25 2012-01-26 Novo Nordisk A/S Peptides for Treatment of Obesity
WO2010065802A2 (en) 2008-12-04 2010-06-10 Palatin Technologies, Inc. Substituted pyrrolidine or imidazolidine melanocortin receptor-specific compounds
WO2010065799A2 (en) 2008-12-04 2010-06-10 Palatin Technologies, Inc. Amine substituted piperidine melanocortin receptor-specific compounds
WO2010065801A1 (en) 2008-12-04 2010-06-10 Palatin Technologies, Inc. Amine substituted piperazine melanocortin receptor-specific compounds
WO2010065800A1 (en) 2008-12-04 2010-06-10 Palatin Technologies, Inc. Hydrazine substituted piperidine melanocortin receptor-specific compounds
EP2210885A1 (en) 2009-01-14 2010-07-28 Santhera Pharmaceuticals (Schweiz) AG Substituted heteroarylpiperidine derivatives as melanocortin-4 receptor modulators
WO2010096854A1 (en) 2009-02-27 2010-09-02 Mimetica Pty Ltd Methods of modulating the activity of the mc3 and/or mc4 receptors and treatment of conditions related to these receptors
WO2010144341A2 (en) 2009-06-08 2010-12-16 Palatin Technologies, Inc. Lactam-bridged melanocortin receptor-specific peptides
UY32690A (es) 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
WO2010144344A2 (en) 2009-06-08 2010-12-16 Palatin Technologies, Inc. Melanocortin receptor-specific peptides
EP2461681A4 (en) 2009-08-05 2013-04-24 Ipsen Pharma Sas USE OF MELANOCORTINS FOR TREATING DYSLIPIDEMIA
CA2809803A1 (en) 2009-08-31 2011-03-03 Tensive Controls, Inc. Stabilized melanocortin ligands
ES2654147T3 (es) * 2009-11-16 2018-02-12 Ipsen Pharma S.A.S. Composiciones farmacéuticas de ligandos del receptor de melanocortina
US20130012432A1 (en) 2010-02-26 2013-01-10 Novo Nordisk A/S Peptides for Treatment of Obesity
BR112012021231A2 (pt) 2010-02-26 2015-09-08 Basf Plant Science Co Gmbh método para acentuar o rendimento em plantas, planta, construto, uso de um construto, método para a produção de uma planta transgênica, partes coletáveis de uma planta, produtos derivados de uma planta, uso de um ácido nucleíco e método para a produção de um produto
PT3539551T (pt) * 2011-12-29 2021-11-04 Rhythm Pharmaceuticals Inc Método de tratamento de distúrbios associados ao recetor de melanocortina-4 em portadores heterozigóticos
RU2019116003A (ru) 2013-03-15 2019-07-17 Ритм Фармасьютикалз, Инк. Фармацевтические композиции
ES2693761T3 (es) * 2013-03-15 2018-12-13 Rhythm Pharmaceuticals, Inc. Composiciones de péptidos
EP3356386B1 (en) * 2015-09-30 2024-02-14 Rhythm Pharmaceuticals, Inc. Method of treating melanocortin-4 receptor pathway-associated disorders

Also Published As

Publication number Publication date
FI3356386T3 (fi) 2024-05-16
CN108431023B (zh) 2022-11-04
BR112018006674A2 (pt) 2018-10-09
AU2021201448A1 (en) 2021-03-25
JP2021102650A (ja) 2021-07-15
SG10202101510XA (en) 2021-03-30
EP4360704A2 (en) 2024-05-01
AU2022279420A1 (en) 2023-01-19
CA3000670A1 (en) 2017-04-06
US20180215790A1 (en) 2018-08-02
DK3356386T3 (da) 2024-05-21
IL258412B2 (en) 2023-06-01
WO2017059076A1 (en) 2017-04-06
KR20180063221A (ko) 2018-06-11
JP2022173426A (ja) 2022-11-18
JP6940853B2 (ja) 2021-09-29
IL258412A (en) 2018-05-31
CN108431023A (zh) 2018-08-21
JP2018531938A (ja) 2018-11-01
EP3356386B1 (en) 2024-02-14
JP2018531937A (ja) 2018-11-01
EP3356386A1 (en) 2018-08-08
CA3000673A1 (en) 2017-04-06
AU2023229494A1 (en) 2023-09-28
WO2017059075A1 (en) 2017-04-06
IL289996A (en) 2022-03-01
IL289996B1 (en) 2023-03-01
US20210169970A1 (en) 2021-06-10
EP3355905A1 (en) 2018-08-08
JP2023078335A (ja) 2023-06-06
AU2016330772A1 (en) 2018-04-19
EP4029513A1 (en) 2022-07-20
IL289996B2 (en) 2023-07-01
US10960046B2 (en) 2021-03-30
MX2023003358A (es) 2023-03-29
HK1259424A1 (zh) 2019-11-29
CN108601816A (zh) 2018-09-28
MA43040A (fr) 2018-08-08
JP7051106B2 (ja) 2022-04-11
MA43038A (fr) 2018-08-08
WO2017059076A8 (en) 2018-04-26
PT3356386T (pt) 2024-05-17
JP2021088611A (ja) 2021-06-10
US20220226425A1 (en) 2022-07-21
US20180311309A1 (en) 2018-11-01
AU2016330773A1 (en) 2018-04-19
IL299541A (en) 2023-02-01

Similar Documents

Publication Publication Date Title
MX2023003358A (es) Agonista del receptor de melanocortina-4 (mc4r) para el tratamiento de trastornos asociados a la via del mc4r.
MX2018015592A (es) Anticuerpos inhibidores de puntos de control biespecificos.
DK3392276T3 (da) Heterodimermolekyle baseret på strukturel CH3-domæne, og fremgangsmåde til fremstilling samt anvendelse deraf
CL2017002413A1 (es) Receptor antigénico quimérico
EA201591872A1 (ru) Способ получения углеводородов
MX2021002897A (es) Metodos de tratamiento y prevencion de la disfuncion endotelial utilizando metil bardoxolona o sus analogos.
EP3228733A4 (en) Method for producing silicon carbide single crystal, and silicon carbide single crystal substrate
MX2019000796A (es) Moleculas multimericas de union a ox40 y usos de las mismas.
DK3828277T3 (da) Sammensætninger, fremgangsmåder og apparatur til syntese af oligonukleotider
UY37018A (es) Inhibidores bicíclicos de pad4
ZA201805947B (en) In-situ process to produce hydrogen from underground hydrocarbon reservoirs
NZ726859A (en) Synthesis of polycyclic-carbamoylpyridone compounds
DK3741874T3 (da) Fremgangsmåde til fremstilling af en tin, der indeholder ikke-kornorienteret siliciumstålplade, en således opnået stålplade og anvendelse deraf
PH12018500122A1 (en) Installation structure for faucet
DK3093891T3 (da) Halvledersubstrat, halvlederindretning og fremgangsmåde til fremstilling af halvledersubstrat
JO3384B1 (ar) مركبات إندول كربونيتريل في صورة معدلات لمستقبل أندروجين انتقائية
SG11201609677WA (en) Method for reducing the chlorine content of organomonophosphites using dimethylaminobutane, triethylamine or triethanolamine
EA201690245A1 (ru) Оптимизированный способ получения композиции, содержащей изомальтулозу
DK3071206T3 (da) Gastrinantagonister (eg yf476, netazepid) til behandling og forebyggelse af osteoporose
MX2016002027A (es) Nuevos anticuerpos anti receptores iib fc-gama y usos de los mismos.
JOP20140008B1 (ar) استخدام العوامل المساعدة لمستقبل ألفا 7 أسيتيل كولين نيكوتينية
MX2018013334A (es) Metodo para producir derivados de espirociclicos cis-alcoxi-sustituidos 1-h-pirrolidina-2,4-diona.
MY174200A (en) Process for reducing the chlorine content of organotetraphosphites
DK3336088T3 (da) Krystalform af orexinreceptorantagonistforbindelse, og fremgangsmåde til fremstilling og anvendelse af denne
GB2539619A (en) Laser-leached polycrystalline diamond and laser-leaching methods and devices